Key Highlights
- Loss was USD 0.06 per share against an estimated USD 0.10 loss, and Revenue of USD 1.03 million beat estimates.
- Symvess sales rose 151% from the second quarter, and 49 hospitals were ordering by the end of September.
- Cash and equivalents were USD 64.5 million, with a net loss of USD 15.5 million for the quarter.
- Management guided fourth quarter Symvess sales to at least double third quarter results after October sales reached USD 800,000.
Humacyte (NASDAQ:HUMA) reported a third quarter 2026 loss of USD 0.06 per share, narrower than the USD 0.10 estimated loss. Revenue of USD 1.03 million exceeded the USD 766,000 estimate. All of it was product revenue from sales of Symvess in the United States, compared with USD 0.7 million a year earlier.
Net loss was USD 15.5 million for the quarter, against USD 17.5 million in the third quarter of 2025. For the nine months, net loss was USD 70.0 million, against USD 16.0 million, a sharp increase from the prior-year nine-month figure. The accumulated Deficit was USD 796.8 million, compared with USD 726.8 million at year end.
Management said commercial adoption accelerated in the third quarter, with sales up 151% from the second quarter to just over USD 1.0 million. The number of hospitals ordering Symvess rose 44%, from 34 at the end of the second quarter to 49 at September 30. October sales reached USD 800,000, and management guided that fourth quarter sales are to at least double the third quarter result at current levels of hospital adoption and physician agreement.
Product revenue since FDA approval for the vascular trauma indication was USD 1.9 million for the nine months of 2026, plus USD 1.4 million for the twelve months of 2025. Contract revenue was minimal in the third quarters of 2026 and 2025, reflecting the completion of a research project.
Costs and Cash
Cost of goods sold in the third quarter included USD 0.6 million for the cost of units recorded as sales and USD 0.8 million primarily consisting of overhead tied to unused production capacity. For the nine months, Cost of Goods Sold included USD 1.2 million for units sold, USD 2.3 million of inventory reserves and USD 1.2 million of unused-capacity overhead.
Cash and cash equivalents were USD 64.5 million, plus USD 0.4 million of restricted cash, at September 30. Working Capital was USD 57.9 million, up from USD 49.4 million at year end. In May 2026 the company implemented a plan to reduce its workforce by approximately 45 employees and defer certain planned spending, and its filing lists the risk that cost-saving measures may be disruptive.
Dialysis Access Application
A main goal for 2026 was preparing and submitting a supplemental Biologics License Application to the FDA for the acellular tissue engineered vessel in dialysis access. The application is to be supported by three Phase 3 studies. In the V012 trial, women on dialysis treated with the vessel achieved functional access and use for dialysis more than three months sooner, and spent significantly more time free of dialysis catheters over the first year, than women who received an arteriovenous fistula, the current standard of care. The company also planned to begin a human study of a coronary tissue application.
The filing's legal proceedings item refers readers to the Legal Matters section of its commitments and contingencies note, which describes the company's general approach to accruing for claims.
Items to Follow
Monthly Symvess sales, hospital adoption counts, the timing of the dialysis access application and the cash balance against ongoing spending are the figures to follow.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...